|
Your
Attorney Litigation New Pharmaceutical York Resources
Page [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] >>
 |
... Nursing Home Malpractice Attorneys. Welding Rod Litigation Lawyers. Attorney Hunter ... New York Birth Injury Lawyers. New York Pharmaceutical Attorneys. New York Auto Accident Lawyers ...
|
|
|
|
 |
... Temporary Attorney - Real Estate, HIRECounsel, US-NY-New York City. Oct 19, Leading Pharmaceutical Company Needs Patent Litigation Attorney, Management Recruiters ...
|
|
|
|
 |
Pharmaceutical litigation Law Firm Wingate, Russotti & Shapiro has been handling cases of dangerous drugs, defective medical devices, personal injury, medical malpractice and wrongful ...
|
|
|
|
 |
... Slater helped achieve a precedent-setting attorney fees award ... was also a member of the litigation team for ... Bar Admissions. State of New York, 1991; US District ...
|
|
|
|
 |
...attorney listing michigan ... attorney litigation new pharmaceutical york ... attorney living power will ... attorney los angeles california...
|
|
|
|
Page [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] >>
|
|
Attorney Litigation New Pharmaceutical York World
News
- Pharmaceutical, Healthcare & Life Sciences
AdvaMed stands by FDA's device approval process David Nexon, senior executive vice president at AdvaMed, defended the FDA's 510(k) process for medical devices after the process was recently criticized by Public Citizen, a consumer advocacy group.
attorney litigation new pharmaceutical york 31 Jul 2010 - SREH Files Required Info for 'Current Info' Tier Status With OTC Markets
NEW YORK, NY--(Marketwire - 07/29/10) - SREH (Pinksheets: SREH - News ) CEO Tony Dibiase announces that the company has furnished all required documents and filings to OTCMarkets to qualify for Current Info Tier status. OTC Markets has implemented a strict information reporting system for non-reporting companies and rates them in accordance to transparency elements from Caveat Emptor to Current ...
attorney litigation new pharmaceutical york 31 Jul 2010 - Forest Laboratories, Inc. Reports First Quarter FY 2011 EPS of $0.39, Including $0.39 Per Share Charge Related to ...
NEW YORK----Forest Laboratories, Inc. , an international pharmaceutical manufacturer and marketer, today announced that diluted earnings per share equaled $0.39 in the first quarter of fiscal 2011.
attorney litigation new pharmaceutical york 31 Jul 2010 - The Lanier Law Firm Files Infringement Lawsuit Over Email Spam Patent
The Lanier Law Firm is announcing a patent infringement lawsuit filed on behalf of Longview, Texas-based InNova Patent Licensing LLC against a group of 36 corporate defendants accused of infringing an InNova patent that represents one of the cornerstones of email communications.
attorney litigation new pharmaceutical york 31 Jul 2010 - Unilever, Sears, Danisco, Time Warner, True North: Intellectual Property
Unilever NV , the worlds second- biggest consumer goods maker, and Syngenta AG are challenging the validity of European patents on breeding processes for tomatoes and broccoli at a hearing that attracted about 150 demonstrators.
attorney litigation new pharmaceutical york 31 Jul 2010 - Health-Fraud Whistleblower Cases May Surge Because of Federal Law Overhaul
Federal fraud cases begun by private citizens against drugmakers, insurers and hospitals will probably surge past last years record numbers, driven by incentives in the new health law.
attorney litigation new pharmaceutical york 31 Jul 2010 - Elan Reports Second Quarter and First Half 2010 Financial Results
DUBLIN----Elan Corporation, plc today reported its second quarter and first half 2010 financial results.
attorney litigation new pharmaceutical york 31 Jul 2010 - J&J Sinks After Lowering Forecast on Medicine Recalls
Johnson & Johnson fell the most in six weeks in New York trading after the company, the worlds largest maker of health products, lowered its full-year earnings forecast because of a series of over-the-counter drug recalls.
attorney litigation new pharmaceutical york 31 Jul 2010 - Eli Lilly, Schlumberger, Amazon, HP, Levi Strauss: Intellectual Property
Eli Lilly & Co. , already facing competition next year for its top-selling drug, lost a court bid over patent protection on its cancer medicine Gemzar , which could lead to generic products as early as November.
attorney litigation new pharmaceutical york 31 Jul 2010 - J&J Lowers Annual Forecast on Impact of Drug Recalls
Johnson & Johnson, the worlds largest health-products company, reported second-quarter earnings increased 7.5 percent, while it lowered its 2010 forecast because of a series of drug recalls.
attorney litigation new pharmaceutical york 31 Jul 2010
|
